BioAge Labs (BIOA) Q3 2026 earnings review
BioAge finishes enrolling its heart-risk trial, but losses rise 66%
BioAge, a drug developer that targets the biology of aging, is paying for bigger trials of its lead pill. Its quarterly loss widened to about $34 million, mostly because spending on BGE-102, its anti-inflammation pill, nearly quadrupled. Chief executive Kristen Fortney said the main heart-risk trial has signed up all its patients. By our math, cash would last about 12 more quarters at this pace, just short of the end of 2029.
| Partner revenue before a one-off cut | $2.0M −3% from a year ago; $0.3M as reported |
|---|---|
| Net loss | $33.5M $20.2M a year ago |
| Cash and investments | $352.3M $381.3M three months earlier |
| Cash runway outlook | Unchanged through 2029 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged, because the heart-risk trial kept its timetable. The bad news: BioAge pushed eye-trial results into the second half of 2027 after a late start.
The question now is which dose of BGE-102 works, and how deeply it lowers inflammation. Either a low dose cuts it nearly as much as in the first human study, or the effect proves weaker and the eye trial matters more. Heart-risk results in the fourth quarter will tell.
🐂 Bull Case
Both BGE-102 Trials Are Now Running
BGE-102 is BioAge's lead drug, a once-daily pill that blocks NLRP3, a protein that switches on inflammation. Chief executive Kristen Fortney said the pill has "a potential best-in-class profile". In its first human study, it cut hsCRP, a blood marker of inflammation, by a median 86%.
This quarter the drug developer finished enrolling QUELL-CV, a mid-stage trial in adults with obesity and high inflammation. In September it also gave the first dose in QUELL-DME, a study in diabetic macular edema, a swelling of the retina that blurs vision. Spending on BGE-102 reached $17.8 million, nearly four times last year's level.
The heart-risk study matters most, because Fortney expects its results to "inform the optimal dose". The eye trial measures sharpness of vision, "the same endpoint used for approval of existing therapies", so a good result could let BioAge move faster to a final-stage trial, Fortney said.
What to watch: the QUELL-CV results due in the fourth quarter, and how far the lowest dose cuts hsCRP. A cut close to the first study's level would give BioAge a clear dose for a larger heart-risk trial.
Novartis Widened Its Research Deal With BioAge
BioAge's only revenue comes from Novartis, which pays it to search data on aging people for new drug targets. In September the two companies amended the deal, and Novartis added $0.9 million of research funding for a wider scope of work.
Because the same payments now cover more work, BioAge reversed $1.7 million of revenue it had already booked. Quarterly revenue therefore fell to $0.3 million. Without that one-off, revenue slipped about 3% from a year ago, by our math, so the underlying work held up.
What to watch: revenue in the fourth quarter, the first full period under the wider deal. A return to the $2 million to $3 million BioAge earned in earlier quarters would show the amendment added work, not just delayed revenue.
🐻 Bear Case
This Quarter's Loss Outpaces the Cash Plan
"With a strong cash position, we are well positioned to advance BGE-102 and our apelin and other programs," chief executive Kristen Fortney said. BioAge holds $352 million in cash and short-term investments and says it will last through 2029.
Research spending rose 63% from a year ago, because both trials of BGE-102, its anti-inflammation pill, ran at once. The net loss, minus stock pay that uses no cash, reached $28.9 million. By our math, cash and investments shrank by about $29 million in the quarter.
- Spending the end-2029 date allows: about $27.1 million a quarter, by our math
- Cash at this quarter's pace: about 12 quarters, against 13 to the end of 2029
The gap is small, but this quarter's loss already sits above the plan's average. BioAge wrote that it expects research costs to "continue to increase substantially for the foreseeable future". So the 2029 date holds only if spending eases after these trials, or if the company sells more shares.
What to watch: the runway date in the annual report, due around March. An earlier date, or new share sales, would show that the trials cost more than the cash plan allowed.
BioAge Moved Eye-Trial Results Later Into 2027
QUELL-DME tests BGE-102, BioAge's anti-inflammation pill, in diabetic macular edema, a swelling of the retina that blurs vision. BioAge said the results will also shape its plans for geographic atrophy, another cause of vision loss.
Earlier this year the drug developer planned to start the trial in mid-2026 and report results in mid-2027. It gave the first dose in September and now expects results in the second half of 2027. So the pill's second test arrives later, while costs for both trials keep running.
What to watch: enrollment progress for the roughly 180-person trial in the next two quarterly reports. Slow enrollment would push results toward 2028 and add cost against a cash plan that already looks tight.
Risks this quarter didn't answer
Three issues from earlier releases got no new information in this quarter's report or filing. Each could still change the case for BGE-102, BioAge's anti-inflammation pill, or for the drug developer's costs.
- Final-stage trial: earlier this year BioAge targeted a final-stage heart-risk trial by the end of 2027; this release did not repeat the date. QUELL-CV results will show whether it still holds.
- Shareholder lawsuit: a court dismissed the claims in March and the plaintiff appealed; its reply is due December 9, and a hearing could follow in early 2027.
- Injectable APJ obesity drug: the release no longer names JiKang Therapeutics, the partner on that program; the next filing should say whether the partnership continues.
👓 Other Themes
BioAge Will Lose Its Small-Company Filing Status
BioAge expects to stop being an emerging growth company and a smaller reporting company on December 31, because it has outgrown the legal size limits. From its first-quarter 2027 report, the drug developer will publish fuller pay and financial disclosures. It will also adopt new accounting rules on the same schedule as larger listed companies.
💲 Other KPIs
The share count rose 28% from a year ago, after a January stock sale and smaller sales through a program that lets BioAge sell shares gradually. Weighted shares grew 19% in the first quarter and 25% in the second. Because each new share spreads the loss, loss per share widened less than the net loss.
Overhead costs, the spending on management, finance and legal work, climbed 12% from a year ago. Growth slowed to 1% in the second quarter, then picked up as BioAge granted new stock options to staff, executives and directors. Lower legal fees offset part of that rise.
Accrued research costs, bills for trial work already done but not yet paid, roughly doubled from $3.6 million at the end of December. The rise matches two trials running at once. Because BioAge has booked these costs but not paid them, this quarter's cash outflow looks smaller than the spending behind it.
🔮 Guidance
Unchanged. BioAge now pins the heart-risk trial's first results to the fourth quarter, inside the second-half timing it gave before. About 160 adults have joined, and each takes the pill or a dummy pill for 12 weeks. The trial measures how far hsCRP, a blood marker of inflammation, falls at each dose.
Delayed. BioAge moved the eye trial's first results from mid-2027 into the second half of that year. The change follows a September start, later than the mid-2026 start it had planned. Each patient takes the pill for 12 weeks, so enrollment speed now decides the date.
Unchanged. BioAge still plans to file its first IND, the application US regulators review before human trials start, for an APJ drug by year-end. APJ drugs copy some effects of exercise, which BioAge calls "an exercise-mimetic approach to obesity". In animal tests, adding one to a GLP-1-type weight-loss drug roughly doubled weight loss.
Unchanged. BioAge still says its cash is "sufficient to fund operations and capital expenses through 2029". That leaves 13 quarters from October. The company has kept the same end date for five quarters while its quarterly losses grew, and the chart sets the two side by side.
❓ Key Questions
Which BGE-102 dose will BioAge take forward?
QUELL-CV tests three doses for 12 weeks. Fortney said the results should shape the dose choice. If the lowest dose works almost as well as the others, the next trial can use it.
Does the 2029 cash date assume spending falls?
By our math, this quarter's loss minus stock pay ran above the average the 2029 date allows. BioAge should say whether it plans lower spending after these trials or counts on new share sales.
Is a final-stage heart-risk trial still planned for 2027?
Earlier this year BioAge targeted the end of 2027 to start a final-stage trial. This release did not repeat the date, and QUELL-CV results will set the dose for any such trial.
Why did the eye-disease trial start late?
BioAge planned to start QUELL-DME in mid-2026 but dosed the first patient in September. The reason matters, because slow site openings or enrollment could also delay the results it now expects in the second half of 2027.
How much revenue will the wider Novartis deal bring?
The September amendment added $0.9 million of funding but cut this quarter's revenue by $1.7 million. BioAge did not say how the wider scope of work changes its quarterly revenue in 2027.